Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 9.60
CLDN's Cash to Debt is ranked higher than
69% of the 1254 Companies
in the Global Biotechnology industry.

( Industry Median: 57.26 vs. CLDN: 9.60 )
CLDN' s 10-Year Cash to Debt Range
Min: 9.6   Max: No Debt
Current: 9.6

Z-Score: 14.16
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -92.30
CLDN's ROE (%) is ranked higher than
60% of the 1150 Companies
in the Global Biotechnology industry.

( Industry Median: -34.19 vs. CLDN: -92.30 )
CLDN' s 10-Year ROE (%) Range
Min: 0   Max: 0
Current: -92.3

ROA (%) -56.59
CLDN's ROA (%) is ranked higher than
62% of the 1259 Companies
in the Global Biotechnology industry.

( Industry Median: -27.46 vs. CLDN: -56.59 )
CLDN' s 10-Year ROA (%) Range
Min: -87.49   Max: -70.06
Current: -56.59

-87.49
-70.06
ROC (Joel Greenblatt) (%) -8107.87
CLDN's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 1232 Companies
in the Global Biotechnology industry.

( Industry Median: -394.00 vs. CLDN: -8107.87 )
CLDN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -26139.34   Max: -9285.58
Current: -8107.87

-26139.34
-9285.58
» CLDN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

CLDN Guru Trades in

CLDN Guru Trades in

CLDN Guru Trades in

Q1 2014

CLDN Guru Trades in Q1 2014

Steven Cohen 34,821 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with CLDN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.85
CLDN's P/B is ranked higher than
81% of the 1351 Companies
in the Global Biotechnology industry.

( Industry Median: 6.43 vs. CLDN: 3.85 )
CLDN' s 10-Year P/B Range
Min: 0   Max: 5.1
Current: 3.85

0
5.1
Current Ratio 19.55
CLDN's Current Ratio is ranked higher than
95% of the 1245 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. CLDN: 19.55 )
CLDN' s 10-Year Current Ratio Range
Min: 2.83   Max: 19.55
Current: 19.55

2.83
19.55
Quick Ratio 19.55
CLDN's Quick Ratio is ranked higher than
95% of the 1245 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. CLDN: 19.55 )
CLDN' s 10-Year Quick Ratio Range
Min: 2.83   Max: 19.55
Current: 19.55

2.83
19.55

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.94
CLDN's Price/Net Cash is ranked higher than
92% of the 1351 Companies
in the Global Biotechnology industry.

( Industry Median: 56.62 vs. CLDN: 3.94 )
CLDN' s 10-Year Price/Net Cash Range
Min: 2.42   Max: 6.26
Current: 3.94

2.42
6.26
Price/Net Current Asset Value 3.94
CLDN's Price/Net Current Asset Value is ranked higher than
92% of the 1351 Companies
in the Global Biotechnology industry.

( Industry Median: 30.86 vs. CLDN: 3.94 )
CLDN' s 10-Year Price/Net Current Asset Value Range
Min: 2.42   Max: 6.26
Current: 3.94

2.42
6.26
Price/Tangible Book 3.86
CLDN's Price/Tangible Book is ranked higher than
85% of the 1351 Companies
in the Global Biotechnology industry.

( Industry Median: 9.90 vs. CLDN: 3.86 )
CLDN' s 10-Year Price/Tangible Book Range
Min: 2.37   Max: 6.11
Current: 3.86

2.37
6.11
Earnings Yield (Greenblatt) -8.80
CLDN's Earnings Yield (Greenblatt) is ranked higher than
69% of the 1235 Companies
in the Global Biotechnology industry.

( Industry Median: -5.70 vs. CLDN: -8.80 )
CLDN' s 10-Year Earnings Yield (Greenblatt) Range
Min: -14.9   Max: 0
Current: -8.8

-14.9
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:72C.Germany,
» More Articles for CLDN

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Nasdaq stocks posting largest percentage decreases Jan 30 2015
Celladon Corporation Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Jan 09 2015
PDF Add to Briefcase File is in Briefcase Jan 09 2015
Celladon Corporation Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Jan 09 2015
These 3 Gold Stocks Climbed Over 11% Today Jan 06 2015
Celladon Corporation Conducts Initial Scale Up of Manufacturing Process for MYDICAR to Commercial... Jan 05 2015
PDF Add to Briefcase File is in Briefcase Jan 05 2015
Energy Spinoffs Transocean Partners, Seventy Seven Energy Tumble Dec 29 2014
CELLADON CORP Files SEC form 8-K, Entry into a Material Definitive Agreement Dec 24 2014
PDF Add to Briefcase File is in Briefcase Dec 18 2014
Celladon Corporation Added to NASDAQ Biotechnology Index Dec 16 2014
Celladon Corporation Added to NASDAQ Biotechnology Index Dec 16 2014
Celladon Corporation (CLDN) Falls: Stock Goes Down 8.6% Dec 12 2014
Celladon Corp. (CLDN) Jumps: Stock Adds 14.7% in Session Dec 10 2014
Celladon Corporation to Present at 11th Global Cardio Vascular Clinical Trial Forum Dec 01 2014
PDF Add to Briefcase File is in Briefcase Dec 01 2014
Celladon Corporation to Present at 11th Global Cardio Vascular Clinical Trial Forum Dec 01 2014
CELLADON CORP Financials Nov 19 2014
Celladon Selected to Present During the "Best of Circulation Research" Symposium at the American... Nov 14 2014
Celladon Selected to Present During the "Best of Circulation Research" Symposium at the American... Nov 14 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK